Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes-Reference-Cited by-同舟云学术

Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes

Published:2023-02 Issue:2 Volume:163 Page:398-406
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Nathan Steven D.,Deng Chunqin,King Christopher S.,DuBrock Hilary M.,Elwing Jean,Rajagopal Sudarshan,Rischard Franz,Sahay Sandeep,Broderick Meredith,Shen Eric,Smith Peter,Tapson Victor F.,Waxman Aaron B.

Funder

National Institute of General Medical Sciences

American Heart Association

National Institutes of Health

United Therapeutics Corporation

National Heart, Lung, and Blood Institute

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference11 articles.

1. The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment;King;Chest,2020

2. Pulmonary hypertension in chronic lung disease;Nathan;Eur Respir J,2019

3. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study;Nathan;Lancet Respir Med,2019

4. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia;Corte;Am J Respir Crit Care Med,2014

5. Inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease;Waxman;N Engl J Med,2021

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non‐invasive prediction of pulmonary vascular disease‐related exercise intolerance and survival in non‐group 1 pulmonary hypertension;European Journal of Heart Failure;2024-07-26

2. Inhaled treprostinil in pulmonary hypertension associated with COPD: PERFECT study results;European Respiratory Journal;2024-05-29

3. Response;CHEST;2024-05

4. Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?;CHEST;2024-05

5. Development of a Tool to Assess the Severity of PH-ILD: A Guide to Assist Therapeutic Choices;2024-03-11